GlaxoSmithKline is jumping into the battle to fight the Zika Virus. The company is known for its seasonal flu vaccine and for being the first to deploy an Ebola candidate vaccine.
“We are at very early stages but we have a very interesting technology which we are developing called self-amplifying micro RNA. It’s a very interesting area for us to pursue,” GlaxoSmithKline CEO Andrew Witty told the FOX Business Network’s Maria Bartiromo.
The company is also preparing a global readiness program for Zika with a new project that could be green-lighted in the U.S. within the next six to nine months.
“We’ve made proposals to global governments to create a permanent standby bi-preparedness research organization based here in the U.S.,” Witty told Fox Business.
GlaxoSmithKline also revealed on Wednesday positive results in the Phase-3 study for sirukamb, a human antibody developed for people with severe rheumatoid arthritis.
No further details about its Zika vaccine have been revealed at this time.